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Altering Oligomerization of EphA2 via Mutations in the Intracellular Domain 
Abstract: 
Eph receptor tyrosine kinases (RTKs) are activated by membrane-bound ligands called 
ephrins. Eph RTKs are divided into two subclasses, each activated by a specific classes of the 
ligand ephrin. The overexpression of Eph receptors is correlated to cancer cell metastasis in several 
different types of cancers. Studies with the EphA2 extracellular domain (ECD) and ephrinA1 
ligand have shown that upon binding of ephrin to the receptor, EphA2 undergoes increased 
oligomerization and activation. This indicates that oligomerization is intimately connected to 
kinase activity. High resolution crystal structures of the EphA2 ECD have revealed some details 
of these ligand bound oligomers, as well as ligand free clusters. Despite these structures, there is 
still no comprehensive understanding of the role that each domain plays in ligand-dependent and 
ligand-free EphA2 oligomerization and activation. Here we report our investigation of the role that 
the intracellular domain (ICD) plays on EphA2 oligomerization. We first deleted the sterile alpha 
motif (SAM) domain from the C-terminus of the protein and measured oligomerization with a 
time-resolved, fluorescence spectroscopy method with single molecule sensitivity, called 
fluorescence correlation spectroscopy (FCS). Deleting the SAM domain from the intracellular 
domain displayed reduced mobility of EphA2, and an increased brightness. From this we 
concluded that the SAM domain has a role in inhibiting oligomerization of the un-liganded, full-
length receptor. In future research, our aim is to investigate the role that other motifs play in 
receptor oligomerization. This work will have clinical applications, especially in cancers where 
EphA2 is mutated or overexpressed. 
Introduction:  
Eph receptor tyrosine kinases are the largest known subfamily of receptor tyrosine kinases.1  
Eph RTKs are divided into two subclasses, EphA and EphB.  Their ligands, ephrin are also divided 
into respective A and B classes. In addition, there are nine different 
EphA RTKs, which bind to six A-ephrin ligands, and six different 
EphB RTKs (as well as EphA4), which bind to three B-ephrin 
ligands.1 These Eph RTKs play a role in many aspects of cells, from 
morphology, to communication.1  What is noteworthy for this project 
is that RTKs conduct biochemical signals across the plasma 
membrane through dimerization.1 Eph RTK activation can be 
characterized by ligand binding, oligomerization followed by the 
phosphorylation of tyrosine residues in the juxtamembrane segment 
(JMS), and kinase domains of the protein.2 Key mutations to 
different domains of Eph RTKs often cause alterations in the dimerization and signaling functions 
of the RTKs.3  Post-activation of these RTKs the protein is internalized and degraded.4,5 In 
addition, Eph RTKs are often thought to be related to cancer metastasis.3  It has been shown that 
in some types of cancers certain Eph RTKs are overexpressed, and many Eph RTK somatic 
mutations are oncogenic mutations.3 
Mutations to Eph RTKs have different effects on the oligomerization, and therefore affect 
cell signaling depending on the domain the mutation is located in.  Eph RTKs have many domains 
Figure 1. Eph receptor tyrosine kinases. 
Diagram showing different domains.  
including: a ligand binding domain, cysteine-rich domain, two consecutive fibronectin III 
domains, a transmembrane domain, juxtamembrane domain, kinase domain, SAM domain, and a 
PDZ binding motif.1 (Fig. 1) Our lab is highly interested in introducing key mutations, via site-
directed mutation and genetic recombination, into each of the domains of Eph RTKs and observing 
the functional outcome on the dimerization of the receptors.  Our lab elucidates changes in 
dimerization, and cell signaling, and how those changes influence cancer cells.   
Results: 
 In order to investigate the functions of each of the domains, two serial truncations were 
performed on the protein.  The fluorescent tag was maintained at the end of the protein despite the 
deletions.  First a truncation was done to remove the SAM 
domain and everything following it, denoted as ΔSAM. A 
second mutation was performed to remove the Kinase domain 
and everything following it, denoted as ΔKS. These mutations 
were performed via site-directed mutagenesis, and the 
plasmid was expressed in a mammalian cell line termed 
DU145, a human prostate cancer cell line.5  DU145 cells were 
selected for the experiment because they express very low 
levels of endogenous EphA2. 
Post-transfection, these cells were used in 
immunoblot assays with and without the ligand EA1-fc using a primary antibody (pY-EphA/B) 
that is against the phospho-dityrosine motif found in the juxtamembrane domain of most Eph 
receptors. (Fig. 3)  Looking at the short exposure time in the unliganed section of the figure the 
Figure 2. Truncation schematic of EphA2 RTK 
wild type and the full length receptors, 
denoted A2WT and A2-GFP 
respectively, there appears to be no 
phosphorylation taking place.  When 
observing the ΔSAM construct (A2ΔS-
GFP) the short incubation with the 
antibody shows increased 
phosphorylation.  This shows that the 
receptor may be active with this 
truncation despite the fact that there is 
no ligand bound. The vector is a part of the 
immunoblot to show a control value for no 
phosphorylation. When the antibodies were 
applied on the ΔSAM construct given the 
ligand EA1-Fc phosphorylation was notably 
higher than either the ΔSAM construct without 
ligand or the full length receptor. (Fig. 4) This 
supports the hypothesis that the kinase domain 
undergoes activation upon the deletion of the 
SAM domain.  Any small amounts of 
phosphorylation shown under the wild type, and full length receptors after long exposure to the 
antibody can be explained by endogenous protein.  DU145 is an excellent candidate for this 
experiment specifically because it has very low levels of endogenous EphA2.   
Figure 3. Western blot of EphA2 constructs without ligand. Figure from 
Shi et. al.5 
Figure 4. Western blot of EphA2 constructs with ligand EA1-Fc. 
Figure from Shi et. al.5 
 Morphological changes can also be observed with the truncation mutations (Fig. 5).  
Examining the morphology of the 
DU145 cells it can be seen that when 
ligand is added to the full length 
receptor (EphA2-GFP) the cells 
cluster.  When no ligand is bound to 
the full length receptor the image 
resembles that of the control for no 
clustering (Vec/Ctl). However, the 
ΔSAM construct (EphA2-ΔS-GFP) 
shows substantial clustering without 
the ligand present.  This clustering is 
similar to what is shown in the image 
of the full length receptor with added 
EA1-Fc ligand. In addition, human growth factor (HGF) normally induces cell scattering, and 
somewhat deters clustering.  It is shown that the full unliganded receptor has no clustering in the 
presence of HGF.  When ligand is added to the receptor, clustering occurs despite the HGF, but 
not quite the amount of clustering seen with the liganded receptor without HGF.  When the ΔSAM 
construct is observed with HGF, it is shown that clustering occurs similar to that of the full length 
receptor with HGF.  This supports the phosphorylation data shown in the previous figure.  The 
receptor seems to undergo activation when missing the ΔSAM domain without ligand being added. 
Figure 5. Image showing morphological, and clustering differences of DU145 
cells with different constructs.  Figure from Shi et. al.5 
 To investigate this idea further, fluorescence correlation spectroscopy (FCS) was used.  
FCS is able to reveal the molecular brightness of the fluorescent protein, the mobility, as well as 
the density of the receptor in the membrane.5 Molecular brightness is a measure of the photons 
emitted from a receptor or a 
complex of receptors per unit 
of time. The molecular 
brightness is directly 
proportional to the amount of 
receptors in a given complex.6 
As an example, having a 
dimer with a fluorescent tag 
would show twice the molecular brightness of a monomer.5 The average molecular brightness of 
the full length receptor is 466 cpsm, and the average molecular brightness of the ΔSAM construct 
is 633 cpsm. (Fig. 6) This shows that the molecular brightness of the ΔSAM construct without 
ligand, is significantly higher than the molecular brightness of the full length receptor without 
ligand.  Src-GFP and Myr-GCN4-GFP are monomer and dimer control values respectively.  Src 
is a known monomer, and the GCN4 portion of Myr-GCN4 forces a dimer conformation.5 The 
molecular brightness of the ΔSAM construct is not significantly different from the dimer control, 
however, is significantly different from the monomer control.  Again it is indicated that the deletion 
of the SAM domain allows oligomers, and activation of the receptor.7 The ΔKinase construct 
(EphA2ΔKS-GFP) showed an even higher molecular brightness than the ΔSAM construct.  In fact, 
the ΔKinase construct seems to be elevated just above the dimer control value.  The difference in 
molecular brightness between the ΔKinase construct and the ΔSAM construct can likely be 
Figure 6. Molecular brightness of EphA2 constructs. Figure from Shi et. al.5 
accredited to differing equilibrium distribution of oligomer states.5 Overall it can be concluded 
based on molecular brightness that the truncated receptors seem to have higher oligomer states. 
 The diffusion coefficients tell a similar story. The diffusion coefficient is a measure of 
mobility of the receptor within 
the membrane. The full length 
receptor has a diffusion 
coefficient value of 0.30 
(μm2/s).  This is about twice the 
value of the ΔSAM construct 
and the ΔKinase construct. 
Mobility in the membrane is 
measured via the diffusion coefficient utilizing fluorescence recovery after photo-bleaching 
(FRAP).  It is concluded that the larger the membrane bound protein is, the slower the rate of 
diffusion.8,9  From the diffusion coefficients of the different constructs, it can be concluded, that 
the mobility of the truncated constructs is greatly reduced due to larger cluster formation.  This 
confirms the previously mentioned idea that deletion of the SAM domain causes activation of the 
receptor regardless of ligand presence.  This also shows that the kinase domain is in no way 
inhibiting activation of the receptor. 
 Overall, from the results it can be concluded that the SAM domain of EphA2 plays a major 
role in the inhibition of receptor activation, and signaling. 
 
 
Figure 7. Diffusion coefficients for the different EphA2 constructs.  Figure from Shi 
et. al.5 
Methods: 
 This project used plasmids that contain human EphA2, and were labeled with eGFP 
fluorescent proteins at the C-terminus. The starting plasmids with not truncation mutates were 
created by our collaborators at Case Western Reserve University.  The nucleic acid sequences of 
these plasmids are known, and have been dissected and annotated using a free program called 
Genome Compiler.  Genome Compiler along with an online tool made by New England Biolabs 
(NEB) were used to design the truncation mutations performed.  E. coli strains used consisted of 
DH5α, NEB5α, and NEB10β. 
 Site-directed mutagenesis was conducted using reagents purchased from NEB.  Primers 
were designed for mutation as previously described.  There are three options for mutation using 
site-directed mutagenesis which are 
substitution, deletion, and insertion. (Fig. 8) 
The goal here is to have primers with a high 
enough annealing affinity that they bind to the template DNA, but not so high that they are not 
able to be easily denatured for replication in Polymerase Chain Reaction (PCR). 
Western blotting was used to measure the phosphorylation of tyrosine within the receptor.  
Western blotting is an experiment that allows a specific protein to be located. The antibody pY-
EphA/B was introduced to bind to our protein, and a secondary antibody was introduced as a 
reporter of the magnitude of primary antibody binding.10 Another method of data collection 
involved a custom built fluorescence microscope.  In order to detect changes in dimerization, 
fluorescence cross-correlation spectroscopy (FCCS) was used. (Fig. 9)  FCCS can monitor 
molecular interactions, enzymatic reactions, and dynamic colocaliztion.11 With use of two 
different colored lasers, and two corresponding photon detectors, the emission of the two 
Figure 8. Site-directed mutagenesis schematic. 
fluorescent proteins can be detected. In this project these fluorophores would be eGFP as 
mentioned previously, and mCherry.  This method allows the cross-correlation of the diffusion of 
proteins to be observed.        
  
Another method to detect oligomerization is fluorescence resonance energy transfer 
(FRET).  FRET is similar to FCCS, except FRET is used to indicate distance on a molecular level.12 
Rather than measured correlated diffusion of fluorophores, FRET measures the energy transferred 
from a fluorophore in an excited electronic state to a chromophore.12 The amount of energy 
transferred between the fluorophores has a direct relation to distance.12 Note that when any 
spectroscopy data is taken for membrane bound receptors, the laser is always focused on the 
lamellipodial region of the cell.5 (Fig. 9) This is to ensure that what is being detected is the result 
of membrane function only.  Luckily any data taken in which an organelle or anything non-
membrane appeared under the laser is noticeable and thrown out as outliers.  Similar outliers 
Figure 9. FCCS schematic with sample curves. Figure from Shi et. al.5 
appear when data is taken too close to the edge of the cell.  All FCS for this project is done in vivo, 
and the cells often move out of the area that the laser is focused on. 
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